Pegylated-Interferon .Alfa. 2B (Peg-Ifn)
Chronic Hepatitis C Virus Infection
Merck Sharp & Dohme LLCprotein_peptidePhase 3Dormant
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 62/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Chronic Hepatitis C Virus Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dasabuvir AbbVie | Phase 3 | A |
Ombitasvir Ain Shams University | Phase 3 | A |
Veruprevir Ain Shams University | Phase 3 | A |
Ribavirin Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | Phase 4 | A |
Sofosbuvir Peking University First Hospital | Phase 4 | A |
View all 50 →
Same molecule, other indications
Pegylated-Interferon .Alfa. 2B (Peg-Ifn) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →